Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal unchange5.550 0.000 (0.000%)
Result Announcements

24/05/2021 16:55

Sino Biopharm (01177) 1Q net up 118.5% to RMB1,914m

[ET Net News Agency, 24 May 2021] Sino Biopharmaceutical Limited (01177) said for the
three months ended 31 March 2020, profit attributable to the owners of the parent was
RMB1,913.5 million, 118.5% higher than that of the same period last year.
Basic earnings per share attributable to the owners of the parent were RMB10.19 cent.
The board of the company has declared the payment of a quarterly dividend of HK2 cents per
Revenue was RMB7,243 million, an increase of 16.4% over the same period last year. (KL)

Remark: Real time quote last updated: 02/12/2021 11:35
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.